Accredited Wealth Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 822.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,718 shares of the company’s stock after buying an additional 3,315 shares during the quarter. Accredited Wealth Management LLC’s holdings in Johnson & Johnson were worth $689,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Aster Capital Management DIFC Ltd raised its position in shares of Johnson & Johnson by 12.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 22,542 shares of the company’s stock worth $4,180,000 after acquiring an additional 2,477 shares during the period. LeClair Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $205,000. Handelsbanken Fonder AB boosted its position in Johnson & Johnson by 29.9% during the third quarter. Handelsbanken Fonder AB now owns 1,880,207 shares of the company’s stock worth $348,628,000 after purchasing an additional 433,283 shares in the last quarter. Generali Investments Management Co LLC increased its position in shares of Johnson & Johnson by 71.4% in the third quarter. Generali Investments Management Co LLC now owns 31,455 shares of the company’s stock valued at $5,832,000 after buying an additional 13,108 shares in the last quarter. Finally, Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $203,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last quarter. Insiders own 0.16% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $248.81 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $248.94. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The company has a 50 day moving average price of $224.67 and a 200 day moving average price of $201.61. The stock has a market capitalization of $599.60 billion, a P/E ratio of 22.52, a PEG ratio of 2.36 and a beta of 0.35.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.
Key Headlines Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Early clinical data: Preliminary Phase 1b results for pasritamig (JNJ‑78278343) combined with docetaxel showed deep PSA responses, a safety profile consistent with docetaxel alone, and plans to advance into Phase 3 — a clear pipeline positive if confirmed. Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
- Positive Sentiment: Pipeline progress & R&D headlines are reinforcing investor confidence in growth beyond legacy products — additional coverage highlights antitumor activity and R&D milestones, supporting longer-term revenue upside. Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
- Positive Sentiment: Momentum and technicals: Analysts and commentary note JNJ is up ~38% over six months and has traded consistently above its 50- and 200-day SMAs — this supports momentum-driven buying and ETF/quant inflows. J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
- Positive Sentiment: Defensive appeal: Published investor pieces emphasize JNJ’s diversified healthcare exposure and reliable dividend, making it attractive in risk-off environments — supporting demand as markets wobble. 2 Reasons I’d Happily Hold Johnson & Johnson Through Any Market Crash
- Neutral Sentiment: Market outperformance note: Coverage flagged that JNJ advanced while the broader market declined today — helpful context for flows but not a fundamental driver by itself. Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
- Negative Sentiment: Litigation risk resurfacing: A Philadelphia jury ordered damages in a talc-related ovarian cancer case — the first plaintiff win since litigation recommenced — reviving product-liability exposure after prior bankruptcy strategies were curtailed. This increases headline and reserve risk. Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves
- Negative Sentiment: Regulatory / competitor legal pressure: Bayer has filed a separate lawsuit related to marketing practices for a prostate cancer drug — adds uncertainty and potential costs. Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
- Five stocks we like better than Johnson & Johnson
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The Biggest IPO Ever… Open to Everyday Folks
- Silver records prices are great. Monthly income is better
- Read this or regret it forever
- Sell this, buy that
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
